Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies

• Main Authors: Rajbharan Yadav (Author), Siddharth Sukumaran (Author), Tanja S. Zabka (Author), Jinze Li (Author), Amy Oldendorp (Author), Gary Morrow (Author), Arthur Reyes (Author), Melissa Cheu (Author), Jessica Li (Author), Jeffrey J. Wallin (Author), Siao Tsai (Author), Laura Sun (Author), Peiyin Wang (Author), Diego Ellerman (Author), Christoph Spiess (Author), Andy Polson (Author), Eric G. Stefanich (Author), Amrita V. Kamath (Author), Meric A. Ovacik (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/pharmaceutics14050970; 1999-4923
• Keywords: T cell-dependent bispecific antibody; CD79b; CD3 binding affinity; pharmacokinetics; pharmacodynamics; target-mediated drug disposition model; Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 14, Iss 5, p 970 (2022)

The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for preclinical characterization. To evaluate the impact of CD3 binding affinity on the TDB pharmacokinetics (PK), we utilized non-tumor-targeting bispecific anti-gD/CD3 antibodies composed of a low/high CD3 affinity arm along with a monospecific anti-gD arm as controls in monkeys and mice. An integrated PKPD model was developed to characterize PK and pharmacodynamics (PD). This study revealed the impact of CD3 binding affinity on anti-cyCD79b/CD3 PK. The surrogate anti-cyCD79b/CD3 TDB was highly effective in killing CD79b-expressing B cells and exhibited nonlinear PK in monkeys, consistent with target-mediated clearance. A dose-dependent decrease in B cell counts in peripheral blood was observed, as expected. Modeling indicated that anti-cyCD79b/CD3 TDB's rapid and target-mediated clearance may be attributed to faster internalization of CD79b, in addition to enhanced CD3 binding. The model yielded unbiased and precise curve fits. These findings highlight the complex interaction between TDBs and their targets and may be applicable to the development of other biotherapeutics.